Treatment success rate and time to culture conversion under a prospective BPaL cohort study

BACKGROUND: In July 2022, Indonesia implemented the 6-month BPaL (bedaquiline, pretomanid, linezolid) regimen under operational research (OR) for selected drug-resistant tuberculosis patients. The study aimed to assess treatment success rate (TSR) and time to sputum culture conversion (TSCC). METHOD...

Full description

Bibliographic Details

Published in:	IJTLD Open
Main Authors:	E. Burhan, J. Sugiharto, M. Soemarno, A. Juan, Y. Runtu, A. Yuvensia, R. Ramadhani, J. Sabono, A. Lailiyah, F. Fenni, M. Farikha, T. Pakasi, I. Pambudi, M. Mbenga, I. Koppelaar, V. Mirtskhulava, F. Wares, D. Jerene, J.K. Jung, J.S. Lee, S. Foraida, S. Juneja, M. Diachenko, A. Gebhard
Format:	Article
Language:	English
Published:	International Union Against Tuberculosis and Lung Disease (The Union) 2025-05-01
Subjects:	cohort studies treatment outcome multidrug-resistant culture conversion bpal indonesia
Online Access:	https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000005/art00007